AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
复制标题
DOI：
10.1093/cid/ciaa1176
复制
发表时间：
2021-08-01
影响因子：
11.8
通讯作者：
Ivachtchenko, Alexandre, V
中科院分区：
文献类型：
--
作者：
Ivashchenko, Andrey A.;Dmitriev, Kirill A.;Ivachtchenko, Alexandre, V
于二零二零年五月，俄罗斯卫生部授予RNA聚合酶抑制剂AVIFAVIR（法匹拉韦）用于治疗COVID-19患者的快速上市许可。在II/III期临床试验的中试阶段，AVIFAVIR使62.5%的患者在4天内清除了SARS-CoV-2病毒，并且安全性和耐受性良好。
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.